<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Rui Tian | PhD Applicant in Biomedical Sciences</title>
    <style>
        :root { --primary: #2c3e50; --secondary: #3498db; --bg: #ffffff; --text: #333; }
        body { font-family: 'Segoe UI', Arial, sans-serif; line-height: 1.6; color: var(--text); max-width: 900px; margin: 0 auto; padding: 40px 20px; background: var(--bg); }
        header { border-bottom: 2px solid #eee; padding-bottom: 20px; margin-bottom: 30px; }
        h1 { color: var(--primary); margin: 0; font-size: 2.5em; }
        h2 { color: var(--primary); border-left: 5px solid var(--secondary); padding-left: 15px; margin-top: 40px; text-transform: uppercase; font-size: 1.2em; }
        .contact-info { margin-top: 10px; color: #666; }
        .contact-info a { color: var(--secondary); text-decoration: none; margin-right: 15px; }
        .pub-item { margin-bottom: 25px; padding-left: 20px; border-left: 2px solid #f0f0f0; }
        .highlight { color: #555; font-size: 0.95em; display: block; margin-top: 5px; font-style: italic; }
        .contribution { color: #2980b9; font-size: 0.9em; display: block; margin-top: 3px; font-weight: 500; }
        .pdf-link { display: inline-block; background: #e74c3c; color: white !important; padding: 2px 8px; border-radius: 3px; font-size: 0.8em; text-decoration: none !important; margin-left: 10px; }
        .pdf-link:hover { background: #c0392b; }
        .me { font-weight: bold; text-decoration: underline; }
        .exp-item { margin-bottom: 25px; }
        .exp-header { display: flex; justify-content: space-between; font-weight: bold; }
    </style>
</head>
<body>

<header>
    <h1>Rui Tian (田睿)</h1>
    <div class="contact-info">
        <a href="mailto:christy.terence0111@gmail.com">christy.terence0111@gmail.com</a> | 
        <span>(+86) 152 2391 4429</span> | 
        <a href="CV-Rui Tian.pdf" target="_blank" style="font-weight:bold;">[View Full CV]</a>
    </div>
    <p><strong>Research Interests:</strong> Translational Cancer Research, Oncolytic Virus (oHSV-1), Tumor Immunotherapy, Bioinformatics.</p>
</header>

<section>
    <h2>Education</h2>
    <div class="exp-item">
        <div class="exp-header"><span>Xiamen University</span><span>09/2019 - 06/2022</span></div>
        <div>Master of Translational Medicine (Biomedicine) | GPA: 84/100</div>
    </div>
    <div class="exp-item">
        <div class="exp-header"><span>Chongqing Medical University</span><span>09/2015 - 06/2019</span></div>
        <div>Bachelor of Sanitary Inspection and Quarantine | Rank: 3/82 (Top 3.7%)</div>
    </div>
</section>

<section>
    <h2>Publications & Contributions</h2>

    <div class="pub-item">
        <span class="me">Rui Tian</span>, et al. "A potent neutralizing and protective antibody against a conserved continuous epitope on HSV glycoprotein D." <em>Antiviral Research</em>, 2022.
        <a href="A potent neutralizing and protective antibody against a conserved continuous epitope on HSV glycoprotein D.pdf" class="pdf-link" target="_blank">PDF</a>
        <span class="highlight">Highlight: Identified a potent neutralizing antibody and mapped a conserved epitope on HSV gD, providing a promising target for broad-spectrum HSV therapy.</span>
        <span class="contribution">My Contribution: Lead author; responsible for manuscript drafting, data processing, antibody identification/evaluation, and epitope exploration.</span>
    </div>

    <div class="pub-item">
        Fei Ju, ..., <span class="me">Rui Tian</span>, et al. "Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response..." <em>Journal for ImmunoTherapy of Cancer</em>, 2022.
        <a href="Oncolytic virus expressing PD-­ 1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-­ 4 or TIM-­ 3 blockade.pdf" class="pdf-link" target="_blank">PDF</a>
        <span class="highlight">Highlight: Demonstrated that oHSV expressing PD-1 inhibitors synergizes with immune checkpoint blockades (CTLA-4/TIM-3) to overcome tumor resistance.</span>
        <span class="contribution">My Contribution: Participated in cell culture, viral production, titration, and experimental data processing.</span>
    </div>

    <div class="pub-item">
        Jing Wu, <span class="me">Rui Tian</span>, et al. "The tumor suppressor DACT3 sensitizes triple-negative breast cancer to apatinib by inhibiting the Wnt/β-catenin pathway." <em>Translational Oncology</em>, 2025.
        <a href="The tumor suppressor DACT3 sensitizes triple-negative breast cancer to apatinib by inhibiting the Wnt:β-catenin pathway.pdf" class="pdf-link" target="_blank">PDF</a>
        <span class="highlight">Highlight: Identified DACT3 as a crucial biomarker for apatinib sensitivity in TNBC, revealing the mechanism of drug resistance through Wnt signaling.</span>
        <span class="contribution">My Contribution: Guided early-stage molecular and cellular experiments; contributed to data analysis and manuscript revision.</span>
    </div>

    <div class="pub-item">
        Mingyu Peng, ..., <span class="me">Rui Tian</span>, et al. "The novel DNA methylation marker FIBIN suppresses non-small cell lung cancer metastasis..." <em>Cellular Signalling</em>, 2024.
        <a href="The novel DNA methylation marker FIBIN suppresses non-small cell lung cancer metastasis by negatively regulating ANXA2.pdf" class="pdf-link" target="_blank">PDF</a>
        <span class="highlight">Highlight: Identified FIBIN as a novel epigenetic marker that suppresses lung cancer metastasis by negatively regulating the ANXA2 pathway.</span>
        <span class="contribution">My Contribution: Participated in bioinformatics/data analysis and manuscript revision.</span>
    </div>

    <div class="pub-item">
        Fengsheng Dai, ..., <span class="me">Rui Tian</span>, et al. "PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype..." <em>Genes & Diseases</em>, 2023.
        <a href="PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype.pdf" class="pdf-link" target="_blank">PDF</a>
        <span class="highlight">Highlight: Established PDCD2 as a key prognostic biomarker in glioma, linking it to immune infiltration and malignant progression.</span>
        <span class="contribution">My Contribution: Participated in statistical data analysis and manuscript revision.</span>
    </div>
</section>

<section>
    <h2>Research Summary</h2>
    <div class="exp-item">
        <strong>Host Intrinsic Restriction Factors for oHSV-1 Resistance</strong>
        <p>Integrated RNA-seq and bioinformatics to identify 16 interferon-related genes (IRGs). Successfully generated 16 CRISPR/Cas9 knockout cell lines to validate HIR factors, elucidating key mechanisms of viral resistance.</p>
    </div>
</section>

</body>
</html>
